Immune checkpoint inhibitor-related acral vasculitis

by Thibault Comont, Vincent Sibaud, Loïc Mourey, Pierre Cougoul, Odile Beyne-Rauzy
Published 2018-11-01

Adapting patients' oncological treatment through remote participation of general practitioners in multi-disciplinary consultation meetings: A feasibility study

by Vladimir Druel, Laetitia Gimenez, Paul Tachousin, Nathalie Boussier, Eric Bauvin, Grosclaude Pascale, Odile Beyne-Rauzy, Marie-Eve Rougé Bugat
Published 2022-12-01

Ribavirin for Chronic Hepatitis Prevention among Patients with Hematologic Malignancies

by Suzanne Tavitian, Jean-Marie Peron, Françoise Huguet, Nassim Kamar, Florence Abravanel, Odile Beyne-Rauzy, Lucie Oberic, Stanislas Faguer, Laurent Alric, Murielle Roussel, Clément Gaudin, Loïc Ysebaert, Anne Huynh, Christian Recher
Published 2015-08-01

Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?

by Olivier Kosmider, Marie Passet, Valeria Santini, Uwe Platzbecker, Valérie Andrieu, Gina Zini, Odile Beyne-Rauzy, Agnès Guerci, Erico Masala, Enrico Balleari, Ekaterina Bulycheva, François Dreyfus, Pierre Fenaux, Michaela Fontenay, Sophie Park
Published 2016-07-01

TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia

by Olivier Kosmider, Véronique Gelsi-Boyer, Marion Ciudad, Cindy Racoeur, Valérie Jooste, Norbert Vey, Bruno Quesnel, Pierre Fenaux, Jean-Noël Bastie, Odile Beyne-Rauzy, Aspasia Stamatoulas, François Dreyfus, Norbert Ifrah, Stéphane de Botton, William Vainchenker, Oliver A. Bernard, Daniel Birnbaum, Michaëla Fontenay, Eric Solary
Published 2009-12-01

S162: LOSS OF HEMATOPOIETIC PROGENITORS HETEROGENEITY IS AN ADVERSE PROGNOSTIC FACTOR IN MYELODYSPLASTIC SYNDROMES

by Charles Dussiau, Thibault Comont, Camille Knosp, Ines Vergnolle, Clotilde Bravetti, Alban Canali, Amandine Houvert, Laetitia Largeaud, Christian Daveaux, Laila Zaroili, Chloe Friedrich, Ismael Boussaid, Loria Zalmai, Carole Almire, Odile Beyne-Rauzy, Lise Willems, Didier Bouscary, Olivier Gandrillon, Michaela Fontenay, Oliver Kosmider, Francois Vergez, Nicolas Chapuis
Published 2023-08-01

Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myélodysplasies

by Charikleia Kelaidi, Aspasia Stamatoullas, Odile Beyne-Rauzy, Emmanuel Raffoux, Bruno Quesnel, Agnes Guerci, François Dreyfus, Sabine Brechignac, Christian Berthou, Thomas Prebet, Yosr Hicheri, Maya Hacini, Jacques Delaunay, Marie-Pierre Gourin, Jean-Marie Camo, Hacene Zerazhi, Anne-Laure Taksin, Laurence Legros, Bachra Choufi, Pierre Fenaux
Published 2010-06-01

Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)

by Pierre Fenaux, Aristoteles Giagounidis, Dominik Selleslag, Odile Beyne-Rauzy, Moshe Mittelman, Petra Muus, Stephen D. Nimer, Eva Hellström-Lindberg, Bayard L. Powell, Agnes Guerci-Bresler, Mikkael A. Sekeres, H. Joachim Deeg, Consuelo del Cañizo, Peter L. Greenberg, Jamile M. Shammo, Barry Skikne, Xujie Yu, Alan F. List
Published 2017-06-01

A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure

by Marie Sébert, Aline Renneville, Cécile Bally, Pierre Peterlin, Odile Beyne-Rauzy, Laurence Legros, Marie-Pierre Gourin, Laurence Sanhes, Eric Wattel, Emmanuel Gyan, Sophie Park, Aspasia Stamatoullas, Anne Banos, Kamel Laribi, Simone Jueliger, Luke Bevan, Fatiha Chermat, Rosa Sapena, Olivier Nibourel, Cendrine Chaffaut, Sylvie Chevret, Claude Preudhomme, Lionel Adès, Pierre Fenaux
Published 2019-08-01

A randomized phase II trial of azacitidine +/− epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents

by Sylvain Thépot, Raouf Ben Abdelali, Sylvie Chevret, Aline Renneville, Odile Beyne-Rauzy, Thomas Prébet, Sophie Park, Aspasia Stamatoullas, Agnes Guerci-Bresler, Stéphane Cheze, Gérard Tertian, Bachra Choufi, Laurence Legros, Jean Noel Bastié, Jacques Delaunay, Marie Pierre Chaury, Laurence Sanhes, Eric Wattel, Francois Dreyfus, Norbert Vey, Fatiha Chermat, Claude Preudhomme, Pierre Fenaux, Claude Gardin
Published 2016-08-01

Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia

by Vincent Jachiet, Guillaume Moulis, Jérome Hadjadj, Julie Seguier, Kamel Laribi, Nicolas Schleinitz, Norbert Vey, Karim Sacre, Bertrand Godeau, Odile Beyne-Rauzy, Romain Bouvet, Jonathan Broner, Natacha Brun, Thibault Comont, Clément Gaudin, Olivier Lambotte, Lenaïg Le Clech, Pierre Peterlin, Frédérique Roy-Peaud, Clémentine Salvado, Mathilde Versini, Françoise Isnard, Jean Emmanuel Kahn, Delphine Gobert, Lionel Adès, Pierre Fenaux, Olivier Fain, Arsène Mekinian
Published 2021-02-01

Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes

by Louise de Swart, Simon Crouch, Marlijn Hoeks, Alex Smith, Saskia Langemeijer, Pierre Fenaux, Argiris Symeonidis, Jaroslav Cermâk, Eva Hellström-Lindberg, Reinhard Stauder, Guillermo Sanz, Moshe Mittelman, Mette Skov Holm, Luca Malcovati, Krzysztof Mądry, Ulrich Germing, Aurelia Tatic, Aleksandar Savic, Antonio Medina Almeida, Njetocka Gredelj-Simec, Agnes Guerci-Bresler, Odile Beyne-Rauzy, Dominic Culligan, Ioannis Kotsianidis, Raphael Itzykson, Corine van Marrewijk, Nicole Blijlevens, David Bowen, Theo de Witte, on behalf of the EUMDS Registry Participants
Published 2020-03-01